おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
IMIDomics
company
About
IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs).
- 11 - 50
Highlights
Details
- Last Funding Type
- Corporate Round
- Industries
- Biotechnology,Health Care
- Founded date
- Jan 1, 2015
- Number Of Employee
- 11 - 50
- Operating Status
- Active
IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, we create value through the combination of the world's largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property. IMIDomics is located at Vall d'Hebron Hospital in Barcelona, Spain and on the HudsonAlpha Institute campus in Huntsville, Alabama.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
—
IMIDomics has raised a total of
—
in funding over 2 rounds. Their latest funding was raised on
Feb 15, 2022 from a Corporate Round round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 15, 2022 | Corporate Round | — | 1 |
Evotec
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
IMIDomics is funded by 1 investors.
Evotec
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Evotec
|
Yes | Corporate Round |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
